Lead Product(s) : Danvatirsen,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : VLAIO
Deal Size : $1.8 million
Deal Type : Funding
Details : The funding will advance Flamingo's RNA-targeting oncology portfolio, including translational research for its lead clinical program, AZD9150 (danvatirsen) in Phase II in head and neck squamous cell carcinoma, and preclinical work on its LncRNA program t...
Product Name : AZD9150
Product Type : Oligonucleotide
Upfront Cash : Undisclosed
June 15, 2023
Lead Product(s) : Danvatirsen,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : VLAIO
Deal Size : $1.8 million
Deal Type : Funding
Lead Product(s) : Danvatirsen,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Dynacure
Deal Size : Undisclosed
Deal Type : Merger
Details : The combined oncology company will advance Flamingo's lead programs, Danvatirsen (antisence oligonucleotide) in a Phase II trial PEMDA-HN in Head & Neck cancer (danvatirsen in combination with pembrolizumab) and other indications; and FTX-001 targeting M...
Product Name : AZD9150
Product Type : Oligonucleotide
Upfront Cash : Undisclosed
February 03, 2023
Lead Product(s) : Danvatirsen,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Dynacure
Deal Size : Undisclosed
Deal Type : Merger
Lead Product(s) : Sitoiganap,Cyclophosphamide,GM-CSF
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Gliovac (sitoiganap/ERC 1671) is an advanced immunotherapy derived from brain tumor tissue that is surgically removed from patients with rGBM,Such tumor tissue is then processed to obtain inactivated intact cells and disrupted lysed cells from different ...
Product Name : Gliovac
Product Type : Vaccine
Upfront Cash : Inapplicable
June 30, 2022
Lead Product(s) : Sitoiganap,Cyclophosphamide,GM-CSF
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Amcenestrant
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Sanofi
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Phase 3 AMEERA-6 study expected to be the first pivotal trial of an oral selective estrogen receptor degrader (SERD) in the adjuvant setting and will evaluate the safety and efficacy of Sanofi’s amcenestrant in ER+ patients who prematurely discontinue ...
Product Name : SAR439859
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
April 06, 2021
Lead Product(s) : Amcenestrant
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Sanofi
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Sitoiganap,Cyclophosphamide,Sargramostim
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The expansion of ERC’s RTT program makes its unique immuno-oncology GBM treatment, ERC1671, available to a wider number of patients who have exhausted all other treatment options.
Product Name : Gliovac
Product Type : Vaccine
Upfront Cash : Inapplicable
July 22, 2020
Lead Product(s) : Sitoiganap,Cyclophosphamide,Sargramostim
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sitoiganap,Cyclophosphamide,Sargramostim
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The MAA contains observations suggesting safety and efficacy of SITOIGANAP demonstrated from the interim data of a randomized double-blind phase II trial.
Product Name : Gliovac
Product Type : Vaccine
Upfront Cash : Inapplicable
June 26, 2020
Lead Product(s) : Sitoiganap,Cyclophosphamide,Sargramostim
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable